Location of Repository

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study

By Marco Colleoni, Anita Giobbie-Hurder, Meredith M. Regan, Beat Thürlimann, Henning Mouridsen, Louis Mauriac, John F. Forbes, Robert Paridaens, István Láng, Ian Smith, Jacquie Chirgwin, Tadeusz Pienkowski, Andrew Wardley, Karen N. Price, Richard D. Gelber, Alan S. Coates and Aron Goldhirsch

Abstract

Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy

Publisher: American Society of Clinical Oncology
Year: 2011
DOI identifier: 10.1200/JCO.2010.31.6455
OAI identifier: oai:edoc.unibas.ch:31707
Provided by: edoc
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://edoc.unibas.ch/dok/A600... (external link)
  • https://edoc.unibas.ch/31707/ (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.